New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)
The relapse rate for children with acute myeloid leukemia (AML) remains high despite advancements in risk classification, multi-agent chemotherapy intensification, stem cell transplantation, and supportive care guidelines. Prognosis for this subgroup of children with relapsed/refractory AML remains...
Saved in:
Main Authors: | Jing Chen (Author), Chana L. Glasser (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2020-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention
by: Thomas Mercher, et al.
Published: (2019) -
Corrigendum: Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention
by: Thomas Mercher, et al.
Published: (2019) -
Targeting MDR1-P-glycoprotein (MDR1-Pgp) in immunochemotherapy of acute myeloid leukemia (AML)
by: Maurizio Cianfriglia
Published: (2013) -
Epigenetic modifications and targeted therapy in pediatric acute myeloid leukemia
by: Huan Xu, et al.
Published: (2022) -
Translocation ETS leukemia-acute myeloid leukemia 1 (TEL-AML1) gene fusion in childhood acute lymphoblastic leukemia
by: Sri Mulatsih, et al.
Published: (2009)